Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Bought by Dynamic Technology Lab Private Ltd

Dynamic Technology Lab Private Ltd increased its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 158.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,090 shares of the specialty pharmaceutical company's stock after purchasing an additional 9,864 shares during the quarter. Dynamic Technology Lab Private Ltd's holdings in Collegium Pharmaceutical were worth $461,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its holdings in shares of Collegium Pharmaceutical by 173.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company's stock valued at $10,711,000 after acquiring an additional 175,892 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Collegium Pharmaceutical in the fourth quarter valued at $2,432,000. Principal Financial Group Inc. grew its position in Collegium Pharmaceutical by 3.9% during the 3rd quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company's stock worth $67,459,000 after purchasing an additional 64,958 shares during the period. Intech Investment Management LLC raised its position in Collegium Pharmaceutical by 593.7% during the fourth quarter. Intech Investment Management LLC now owns 67,132 shares of the specialty pharmaceutical company's stock valued at $1,923,000 after acquiring an additional 57,455 shares in the last quarter. Finally, Janus Henderson Group PLC grew its position in Collegium Pharmaceutical by 399.4% during the third quarter. Janus Henderson Group PLC now owns 69,485 shares of the specialty pharmaceutical company's stock valued at $2,686,000 after buying an additional 55,572 shares during the period.

Remove Ads

Collegium Pharmaceutical Stock Performance

COLL traded up $0.33 during trading on Monday, reaching $26.63. The company's stock had a trading volume of 25,774 shares, compared to its average volume of 441,736. Collegium Pharmaceutical, Inc. has a 52-week low of $23.23 and a 52-week high of $42.29. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The company's fifty day moving average price is $29.14 and its 200-day moving average price is $31.55. The company has a market capitalization of $855.68 million, a price-to-earnings ratio of 11.48 and a beta of 0.76.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The firm had revenue of $181.95 million during the quarter, compared to the consensus estimate of $179.68 million. On average, equities analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Insider Activity

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 26,067 shares of Collegium Pharmaceutical stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $28.50, for a total value of $742,909.50. Following the transaction, the executive vice president now owns 108,137 shares in the company, valued at $3,081,904.50. This trade represents a 19.42 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Colleen Tupper sold 10,445 shares of the firm's stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $30.01, for a total value of $313,454.45. Following the completion of the transaction, the chief financial officer now owns 165,246 shares in the company, valued at approximately $4,959,032.46. This trade represents a 5.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 81,693 shares of company stock valued at $2,334,994 over the last 90 days. Insiders own 3.98% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. StockNews.com raised shares of Collegium Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research note on Friday. HC Wainwright reaffirmed a "buy" rating and set a $50.00 target price on shares of Collegium Pharmaceutical in a report on Monday, March 24th. Piper Sandler cut their price objective on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating for the company in a report on Tuesday, February 4th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $46.00 price objective on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $43.60.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.